Australia is eagerly awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://graysonfhqv315446.ampedpages.com/this-new-drug-retatrutide-australia-a-new-solution-for-obesity-treatment-69875267